Dernières nouvelles pour Nektar Therapeutics (NASDAQ:NKTR) Stock

NEKTAR THERAPEUTICS

Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 26.32 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $10.46 million which missed the analyst consensus estimate of $15.36 million by 31.89 percent. This is a 51.66 percent decrease over sales of $21.64 million the same period last year.

Earnings

Earnings Misses

News

NKTR

Nektar Therapeutics Q1 EPS $(0.24) Misses $(0.16) Estimate, Sales $10.46M Miss $15.36M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) will release its quarterly earnings report on Thursday, 2025-05-08. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Nektar Therapeutics to report an earnings per share (EPS) of $-0.18.
The market awaits Nektar Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 0.56% drop in the share price the following trading session.
Here's a look at Nektar Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.19</td>
<td>-0.21</td>
<td>-0.20</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.18</td>
<td>-0.25</td>
<td>-0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-8.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746634186_0.png" alt="eps graph" />
<h3>Market Performance of Nektar Therapeutics's Stock</h3>
Shares of Nektar Therapeutics were trading at $0.642 as of May 06. Over the last 52-week period, shares are down 61.72%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Nektar Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Nektar Therapeutics.
A total of 4 analyst ratings have been received for Nektar Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $5.25, suggesting a potential 717.76% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of scPharmaceuticals and Aclaris Therapeutics, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for scPharmaceuticals, with an average 1-year price target of $16.5, suggesting a potential 2470.09% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Aclaris Therapeutics, with an average 1-year price target of $15.0, suggesting a potential 2236.45% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for scPharmaceuticals and Aclaris Therapeutics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nektar Therapeutics</td>
<td>Buy</td>
<td>22.15%</td>
<td>$21.20M</td>
<td>13.25%</td>
</tr>
<tr>
<td>scPharmaceuticals</td>
<td>Buy</td>
<td>99.31%</td>
<td>$8.19M</td>
<td>-85.60%</td>
</tr>
<tr>
<td>Aclaris Therapeutics</td>
<td>Outperform</td>
<td>-47.58%</td>
<td>$-90K</td>
<td>-67.59%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Nektar Therapeutics ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the highest return on equity compared to its peers.
<h3>Delving into Nektar Therapeutics's Background</h3>
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
<h3>Unraveling the Financial Story of Nektar Therapeutics</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Nektar Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 22.15%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nektar Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.89%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Nektar Therapeutics's ROE excels beyond industry benchmarks, reaching 13.25%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nektar Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.37% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Nektar Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.69.
<a href="https://www.benzinga.com/quote/NKTR/earnings">To track all earnings releases for Nektar Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Nektar Therapeutics's Earnings: A Preview

WIIM

Nektar Therapeutics shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1 to $2.

In the preceding three months, 5 analysts have released ratings for Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Nektar Therapeutics, presenting an average target of $5.5, a high estimate of $6.50, and a low estimate of $2.00. Observing a 7.42% increase, the current average has risen from the previous average price target of $5.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1744380037_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nektar Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Roger Song &#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $2.00&#x7C;$1.00 &#x7C; 
&#x7C;Jay Olson &#x7C;Oppenheimer &#x7C;Announces &#x7C;Outperform &#x7C; $6.00&#x7C;- &#x7C; 
&#x7C;Arthur He &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $6.50&#x7C;$6.50 &#x7C; 
&#x7C;Arthur He &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $6.50&#x7C;$6.50 &#x7C; 
&#x7C;Arthur He &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $6.50&#x7C;$6.50 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nektar Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nektar Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Nektar Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nektar Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NKTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nektar Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Nektar Therapeutics Better</h2>
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
<h3>Financial Milestones: Nektar Therapeutics's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Nektar Therapeutics displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 22.15%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Nektar Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.89% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 13.25%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.37%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 1.69, Nektar Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts

Jefferies analyst Roger Song upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Hold to Buy and raises the price target from $1 to $2.

Upgrades

Price Target

Jefferies Upgrades Nektar Therapeutics to Buy, Raises Price Target to $2

Offerings

Nektar Therapeutics: Files For Mixed Shelf Offering Of Up To $300M

Nekar Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a price target of $6.

Oppenheimer analyst Jay Olson upgrades Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) from Perform to Outperform and announces $6 price target.

Oppenheimer Upgrades Nektar Therapeutics to Outperform, Announces $6 Price Target

<h3>Gainers</h3>
<ul>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) shares moved upwards by 17.1% to $1.51 during Friday's pre-market session. The company's market cap stands at $151.1 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock rose 15.46% to $1.12. The company's market cap stands at $18.6 million. </li>
<li>Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) stock increased by 14.72% to $16.75. The company's market cap stands at $436.3 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 11.64% to $0.91. The company's market cap stands at $167.9 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) stock rose 10.67% to $1.14. The market value of their outstanding shares is at $17.5 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock rose 10.09% to $3.6. The company's market cap stands at $3.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares decreased by 16.33% to $2.46. The company's market cap stands at $142.3 million. The company's, Q4 earnings came out today. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock fell 16.0% to $1.05. The company's market cap stands at $86.5 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock decreased by 15.49% to $3.41. The market value of their outstanding shares is at $119.4 million. </li>
<li>Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) shares decreased by 15.34% to $3.7. The company's market cap stands at $274.7 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 15.26% to $1.0. The market value of their outstanding shares is at $10.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADGM

AIRS

CLLS

ETON

IRIX

MRKR

OLMA

REVB

SERA

SHPH

STRO

12 Health Care Stocks Moving In Friday's Pre-Market Session

4 analysts have expressed a variety of opinions on Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.88, a high estimate of $6.50, and a low estimate of $4.00. This current average has decreased by 9.54% from the previous average price target of $6.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870850_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Nektar Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Arthur He</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.50</td>
<td>$6.50</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nektar Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nektar Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Nektar Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Nektar Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NKTR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nektar Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Nektar Therapeutics's Background</h2>
Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).
<h3>Nektar Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Nektar Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -0.08% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Nektar Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -153.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -57.64%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Nektar Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.38%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Nektar Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 2.21. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Nektar Therapeutics: Insights From 4 Financial Analysts

HC Wainwright &amp; Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) with a Buy and maintains $6.5 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $6.5 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.17) by 11.76 percent. The company reported quarterly sales of $29.200 million which missed the analyst consensus estimate of $29.860 million by 2.21 percent. This is a 22.25 percent increase over sales of $23.885 million the same period last year.

Earnings Beats

Nektar Therapeutics Q4 2024 Adj. EPS $(0.15) Beats $(0.17) Estimate, Sales $29.200M Miss $29.860M Estimate

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

AEYE

AMRN

ANIK

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CDLX

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

HBIO

IRBT

KEQU

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

MOMO

NESR

NSPR

NVGS

ONDS

OPRX

PATH

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

SNES

TLYS

UPLD

VNET

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

Nektar Therapeutics Announces Completion Of Target Enrollment In REZOLVE-AA Phase 2b Clinical Trial Of Rezpegaldesleukin In Patients With Severe-to-Very Severe Alopecia Areata

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

Nektar Therapeutics shares are trading higher after the company received Fast Track designation for Rezpegaldesleukin for the treatment of moderate-to-severe atopic dermatitis.

Biotech

Health Care

General

The FDA Has Granted Fast Track Designation To Nektar Therapeutics' Rezpegaldesleukin For Adult And Pediatric Patients 12 Years Of Age And Older With Moderate-to-severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled With Topical Prescription Therapies Or When Those Therapies Are Not Advisable

<h3>Gainers</h3>
<ul>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) stock rose 30.9% to $25.0 during Monday's pre-market session. The market value of their outstanding shares is at $598.5 million. </li>
<li>Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) shares increased by 21.88% to $22.0. The market value of their outstanding shares is at $7.3 billion. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares rose 18.43% to $3.02. The market value of their outstanding shares is at $84.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 16.84% to $0.79. The market value of their outstanding shares is at $145.7 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares rose 12.74% to $0.49. The company's market cap stands at $9.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock increased by 12.5% to $3.24. The company's market cap stands at $129.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares declined by 57.6% to $3.3 during Monday's pre-market session. The company's market cap stands at $200.8 million. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) stock declined by 24.87% to $5.0. The market value of their outstanding shares is at $7.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock fell 19.59% to $11.21. The company's market cap stands at $862.6 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares decreased by 17.55% to $2.35. The company's market cap stands at $3.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 15.13% to $1.01. The market value of their outstanding shares is at $33.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock declined by 12.05% to $5.11. The market value of their outstanding shares is at $51.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CUTR

CYTH

MBOT

OPTN

PLRX

PRPO

PRTC

REPL

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press Releases

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Comments

Nektar Therapeutics

Actualités

Dernières nouvelles pour Nektar Therapeutics (NASDAQ:NKTR) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL